Medical Xpress November 5, 2024
Dennis Thompson

Poorer folks’ access to blockbuster weight-loss drugs through Medicaid remains limited, a new KFF analysis has found. Only 13 states currently allow Medicaid to cover treatment of obesity using glucagon-like peptide-1 agonist (GLP-1) medications, researchers discovered.

Under the Medicaid system, individual states are allowed to decide whether to cover GLP-1 drugs, which include Wegovy (semaglutide), Zepbound (tirzepatide) and Saxenda (liraglutide), the KFF report noted.

Among those states that don’t cover the drugs, half reported that they are considering adding coverage in the near future, the researchers added.

But GLP-1 drugs are pricey, and nearly two-thirds of states said cost is a hurdle to approving coverage of the meds through Medicaid.

“Expanding Medicaid coverage of these drugs could increase access for...

Today's Sponsors

LEK
ZeOmega

Today's Sponsor

LEK

 
Topics: Biotechnology, Govt Agencies, Insurance, Medicaid, Patient / Consumer, Pharma / Biotech, Provider, States, Survey / Study, Trends
Redesigning Integrated Care For Dually Eligible People With Intellectual/Developmental Disabilities
Medicaid spending on weight loss, diabetes drugs up 500% since 2019: 5 numbers to know
CMS Launches New Program for Mental Health, OUD Treatment
Georgia Medicaid shakeup could force 3 in 4 beneficiaries to change plans: Centene CEO
New Center to Coordinate Between Medicaid, Maternal and Child Health

Share This Article